Project Details
| Status | Active |
|---|---|
| Effective start/end date | 21/10/24 → 20/10/29 |
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
- Webber, Kate (Primary Chief Investigator (PCI))
Project: Research